China's Porton Biologics is committed to building an end-to-end gene and cell therapy CDMO service platform. The Opening Ceremony of Porton Biologics Gene and Cell Therapy CDMO Platform was held last week in Suzhou, China.

The phase I construction of the project has been completed. R&D labs of 1200 m2 and GMP workshops of 4000 m2 have been all put into use, so as to provide CDMO services integrating "plasmid, viral vector and cell therapy", satisfying the needs of customers from process development to clinical GMP production. Porton Biologics is also actively engaged in the planning of commercial production. The phase II project, covering a total area of about 16,000 m2, will be settled in Suzhou BioBAY to further improve the capacity in gene and cell therapy process development and commercial production.

Ju Nianfeng, Chairman of Porton Biologics, said, "With over 15 years of efforts, Porton has built a small molecule CDMO platform providing world-leading technologies and services. Now, we put a great amount of effort in the gene and cell therapy CDMO services, as we aim to build a world-leading R&D and production platform depending on core talents and technical skills."

Porton Biologics has advantages in its talent team experienced in scientific research and management, unique technologies (patents and gene therapy platforms), well-established production lines and facilities, and 15-year successful experience of its parent company, Porton.